Patents by Inventor Rosa Armstrong
Rosa Armstrong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5413989Abstract: Activin is administered systemically and locally to induce the growth of mature bone. Activin enhances the level of bone formation and the quality of the bone formed when administered locally with BMP or bone marrow. Administration of activin by subcutaneous route promotes systemic increase in the bone mass.Type: GrantFiled: May 3, 1993Date of Patent: May 9, 1995Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Yasushi Ogawa, David K. Schmidt, Rosa Armstrong, Ranga Nathan, Andrea Y. Thompson, Saeid M. Seyedin
-
Patent number: 5393739Abstract: Bone morphogenetic proteins -2 and -3 (BMPs -2 and -3) work in synergistic combination with TGF-.beta.z to provide compositions with increased osteogenic activity. Methods of treating bone defects, inducing bone growth and increasing bone marrow cell production using these compositions are also disclosed.Type: GrantFiled: September 15, 1993Date of Patent: February 28, 1995Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Hanne Bentz, Andrea Y. Thompson, Rosa Armstrong, David M. Rosen
-
Patent number: 5258029Abstract: Stress-bearing prostheses for replacement or partial replacement of stress-bearing bone are fixed in place by bony ingrowth by providing a stress-bearing member having a porous region in combination with an osteogenic factor extract or a purified osteogenic inductive protein, optionally in combination with a TGF-beta cofactor, in a pharmaceutically acceptable carrier. The carrier is preferably either a collagen composition or a ceramic.Type: GrantFiled: May 23, 1990Date of Patent: November 2, 1993Assignee: Collagen CorporationInventors: George H. Chu, Rosa Armstrong, Robert Chang
-
Patent number: 5208219Abstract: Activin is administered systemically and locally to induce the growth of mature bone. Activin enhances the level of bone formation and the quality of the bone formed when administered locally with BMP or bone marrow. Administration of activin by subcutaneous route promotes systemic increase in the bone mass.Type: GrantFiled: February 14, 1991Date of Patent: May 4, 1993Assignee: Celtrix Pharmaceuticals Inc.Inventors: Yasushi Ogawa, David K. Schmidt, Rosa Armstrong, Ranga Nathan, Andrea Y. Thompson, Saeid M. Seyedin
-
Patent number: 5207710Abstract: Stress-bearing prostheses for replacement or partial replacement of stress-bearing bone are fixed in place by bony ingrowth by providing a stress-bearing member having a porous region in combination with an osteogenic factor extract or a purified osteogenic inductive protein, optionally in combination with a TGF-beta cofactor, in a pharmaceutically acceptable carrier. The carrier is preferably either a collagen composition or a ceramic.Type: GrantFiled: January 10, 1992Date of Patent: May 4, 1993Assignee: Collagen CorporationInventors: George H. Chu, Rosa Armstrong, Robert Chang
-
Patent number: 5118667Abstract: Bone growth factors are used to stimulate new bone formation when administered with agents that inhibit bone resorption. These therapeutic combinations result in an enhanced rate of bone formation with an increase in bone mass.Type: GrantFiled: May 3, 1991Date of Patent: June 2, 1992Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Steven W. Adams, Rosa Armstrong, David Rosen
-
Patent number: 5108436Abstract: Stress-bearing prostheses for replacement or partial replacement of stress-bearing bone are fixed in place by bony ingrowth by providing a stress-bearing member having a porous region in combination with an osteogenic factor extract or a purified osteogenic inductive protein, optionally in combination with a TGF-beta cofactor, in a pharmaceutically acceptable carrier. The carrier is preferably either a collagen composition or a ceramic.Type: GrantFiled: November 23, 1988Date of Patent: April 28, 1992Assignee: Collagen CorporationInventors: George H. Chu, Rosa Armstrong, Robert Chang
-
Patent number: 5008240Abstract: Inflammation, acute and/or chronic, is treated with a CIF (TGF-.beta.). The CIF may be administered locally or systemically, depending upon the indication, and does not require coadministration or activator or cofactor for efficacy.Type: GrantFiled: August 9, 1988Date of Patent: April 16, 1991Assignee: Collagen CorporationInventors: Hanne Bentz, Larry Ellingsworth, Rosa Armstrong
-
Patent number: 4971952Abstract: Inflammation, acute and/or chronic, is treated with a CIF (TGF-beta). The CIF may be administered locally or systemically, depending upon the indication, and does not require coadministration of activator or cofactor for efficacy.Type: GrantFiled: October 27, 1988Date of Patent: November 20, 1990Assignee: Collagen CorporationInventors: Hanne Bentz, Larry Ellingsworth, Rosa Armstrong
-
Patent number: 4843063Abstract: Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to hmogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.Type: GrantFiled: June 8, 1988Date of Patent: June 27, 1989Assignee: Collagen CorporationInventors: Saeid Seyedin, Thomas Thomas, Hanne Bentz, Larry Ellingsworth, Rosa Armstrong
-
Patent number: 4810691Abstract: Two proteins that are found is bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.Type: GrantFiled: December 10, 1987Date of Patent: March 7, 1989Assignee: Collagen CorporationInventors: Saeid Seyedin, Thomas Thomas, Hanne Bentz, Larry Ellingsworth, Rosa Armstrong
-
Patent number: 4806523Abstract: Inflammation, acute and/or chronic, is treated with a CIF (TGF-.beta.). The CIF may be administered locally or symstemically, depending upon the indication, and does not require coadministraion of activator or cofactor for efficacy.Type: GrantFiled: March 6, 1986Date of Patent: February 21, 1989Assignee: Collagen CorporationInventors: Hanne Bentz, Larry Ellingsworth, Rosa Armstrong
-
Patent number: 4789663Abstract: A method of repairing bone defects by use of suspensions containing purified atelopeptide, reconstituted, fibrillar skin collagen or bone collagen powder or mixtures thereof is disclosed. The suspensions provide matrices for conductive growth of bone into the defect. The skin collagen may also be lyophilized and used in the form of mats.Type: GrantFiled: July 5, 1985Date of Patent: December 6, 1988Assignee: Collagen CorporationInventors: Donald G. Wallace, Thomas L. Smestad, John M. McPherson, Karl A. Piez, Saeid Seyedin, Rosa Armstrong
-
Patent number: 4774322Abstract: Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.Type: GrantFiled: December 10, 1987Date of Patent: September 27, 1988Assignee: Collagen CorporationInventors: Saeid Seyedin, Thomas Thomas, Hanne Bentz, Larry Ellingsworth, Rosa Armstrong
-
Patent number: 4774228Abstract: Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.Type: GrantFiled: December 10, 1987Date of Patent: September 27, 1988Assignee: Collagen CorporationInventors: Saeid Seyedin, Thomas Thomas, Hanne Bentz, Larry Ellingsworth, Rosa Armstrong
-
Patent number: RE34090Abstract: Two proteins that are found is bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.Type: GrantFiled: March 5, 1991Date of Patent: October 6, 1992Assignee: Celtrix Laboratories, Inc.Inventors: Saeid Seyedin, Thomas Thomas, Hanne Bentz, Larry Ellingsworth, Rosa Armstrong
-
Patent number: RE35694Abstract: Two proteins that are found in bone and that have in vivo chondrogenic/osteogenic activity in combination with a co-factor are described. Both proteins also were active in combination with EGF in the in vitro TGF-.beta. assay. Each has a molecular weight of approximately 26,000 daltons by SDS-PAGE. Each is reduced to a single polypeptide indicating that the proteins are probably homodimers. One has an N-terminal sequence identical to that of human placenta-derived TGF-.beta. whereas the other has an N-terminal sequence that is different from that of TGF-.beta. derived from human placenta. The two proteins may be purified to homogeneity using RP-HPLC or acetic acid-urea gel electrophoresis.Type: GrantFiled: June 9, 1994Date of Patent: December 16, 1997Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Saeid Seyedin, Thomas Thomas, Hanne Bentz, Larry Ellingsworth, Rosa Armstrong